Trial Profile
A Long-Term Non-Interventional Registry to Assess Safety and Effectiveness of HUMIRA® (Adalimumab) in Subjects With Moderately to Severely Active Crohn's Disease (CD)
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Adalimumab (Primary)
- Indications Crohn's disease
- Focus Adverse reactions
- Acronyms PYRAMID
- Sponsors Abbott Laboratories; AbbVie
- 05 Jun 2018 Final results (n=5025) published in the American Journal of Gastroenterology
- 01 Nov 2017 Results of a subgroup analysis assessing long-term safety and effectiveness of Adalimumab by Baseline Immunomodulator use, presented at the 25th United European Gastroenterology Week
- 01 Nov 2017 Results assessing the long-term safety of Adalimumab by age subgroups (n=5025) presented at the 25th United European Gastroenterology Week